Search research articles
Contact Us
Filters
Showing results (211-220 of 263) with videos related to
Page
of 27
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 6, 2010
Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer
Marc Peeters, Timothy Jay Price, Andrés Cervantes, et al.
Histopathology
|
November 29, 2024
Unexpectedly high variability in determining tumour extent in prostatic biopsies: implications for active surveillance
Marit Bernhardt, Leonie Weinhold, Felix Bremmer, et al.
European Urology Oncology
|
February 26, 2022
TROP2 Expression Across Molecular Subtypes of Urothelial Carcinoma and Enfortumab Vedotin-resistant Cells
Jonathan Chou, Kai Trepka, Martin Sjöström, et al.
Histopathology
|
July 25, 2022
Prostatic malakoplakia: clinicopathological assessment of a multi-institutional series of 49 patients
Andres M Acosta, Ankur R Sangoi, Fiona Maclean, et al.
The Lancet. Oncology
|
October 18, 2015
Organ preservation for clinical T2N0 distal rectal cancer using neoadjuvant chemoradiotherapy and local excision (ACOSOG Z6041): results of an open-label, single-arm, multi-institutional, phase 2 trial
Julio Garcia-Aguilar, Lindsay A Renfro, Oliver S Chow, et al.
Journal for Immunotherapy of Cancer
|
May 13, 2021
<i>TERT</i> promoter mutations and other prognostic factors in patients with advanced urothelial carcinoma treated with an immune checkpoint inhibitor
Ivan de Kouchkovsky, Li Zhang, Errol J Philip, et al.
Ebiomedicine
|
February 20, 2026
Fusing data from CT deep learning, CT radiomics and peripheral blood immune profiles to diagnose lung cancer in a cohort of patients experiencing symptoms
Rami Mustapha, Balaji Ganeshan, Sam Ellis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 23, 2022
CUB Domain-Containing Protein 1 (CDCP1) Is a Target for Radioligand Therapy in Castration-Resistant Prostate Cancer, including PSMA Null Disease
Ning Zhao, Shalini Chopra, Kai Trepka, et al.
The Prostate
|
July 21, 2025
Prognostic Impact of Lymph Node Yield in a Phase III Clinical Trial (NRG/RTOG 9601) of Prostate Cancer Patients Treated With Salvage Radiation Following Prostatectomy
Emily Chan, Stephanie L Pugh, Jeffry P Simko, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 18, 2023
CD46-Targeted Theranostics for PET and 225Ac-Radiopharmaceutical Therapy of Multiple Myeloma
Anju Wadhwa, Sinan Wang, Bonell Patiño-Escobar, et al.
Page
of 27
Search research articles
Search
Showing results (211-220 of 263) with videos related to
Sort By:
Page
of 27
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 6, 2010
Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer
Marc Peeters, Timothy Jay Price, Andrés Cervantes, et al.
Histopathology
|
November 29, 2024
Unexpectedly high variability in determining tumour extent in prostatic biopsies: implications for active surveillance
Marit Bernhardt, Leonie Weinhold, Felix Bremmer, et al.
European Urology Oncology
|
February 26, 2022
TROP2 Expression Across Molecular Subtypes of Urothelial Carcinoma and Enfortumab Vedotin-resistant Cells
Jonathan Chou, Kai Trepka, Martin Sjöström, et al.
Histopathology
|
July 25, 2022
Prostatic malakoplakia: clinicopathological assessment of a multi-institutional series of 49 patients
Andres M Acosta, Ankur R Sangoi, Fiona Maclean, et al.
The Lancet. Oncology
|
October 18, 2015
Organ preservation for clinical T2N0 distal rectal cancer using neoadjuvant chemoradiotherapy and local excision (ACOSOG Z6041): results of an open-label, single-arm, multi-institutional, phase 2 trial
Julio Garcia-Aguilar, Lindsay A Renfro, Oliver S Chow, et al.
Journal for Immunotherapy of Cancer
|
May 13, 2021
<i>TERT</i> promoter mutations and other prognostic factors in patients with advanced urothelial carcinoma treated with an immune checkpoint inhibitor
Ivan de Kouchkovsky, Li Zhang, Errol J Philip, et al.
Ebiomedicine
|
February 20, 2026
Fusing data from CT deep learning, CT radiomics and peripheral blood immune profiles to diagnose lung cancer in a cohort of patients experiencing symptoms
Rami Mustapha, Balaji Ganeshan, Sam Ellis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 23, 2022
CUB Domain-Containing Protein 1 (CDCP1) Is a Target for Radioligand Therapy in Castration-Resistant Prostate Cancer, including PSMA Null Disease
Ning Zhao, Shalini Chopra, Kai Trepka, et al.
The Prostate
|
July 21, 2025
Prognostic Impact of Lymph Node Yield in a Phase III Clinical Trial (NRG/RTOG 9601) of Prostate Cancer Patients Treated With Salvage Radiation Following Prostatectomy
Emily Chan, Stephanie L Pugh, Jeffry P Simko, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 18, 2023
CD46-Targeted Theranostics for PET and 225Ac-Radiopharmaceutical Therapy of Multiple Myeloma
Anju Wadhwa, Sinan Wang, Bonell Patiño-Escobar, et al.
Page
of 27